- Home
- OMH vs BRNS Comparison
OMH vs BRNS Comparison
Compare OMH & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMH | BRNS |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 24.1M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OMH | BRNS |
|---|---|---|
| Price | $0.80 | $0.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 32.3K | 20.8K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.59 | $0.51 |
| 52 Week High | $3.25 | $2.91 |
Technical Indicators
Market Signals| Indicator | OMH | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 39.93 | 54.23 |
| Support Level | $0.75 | $0.65 |
| Resistance Level | $1.38 | $0.75 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 9.27 | 48.96 |
Price Performance
Historical ComparisonAbout OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.